Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series
| Autor: | Carl J. Cardella, S. Joseph Kim, Mark S. Cattral, David Z.I. Cherney, Jeffrey Schiff, Harindra Rajasekeran, Sunita K. Singh |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Population 030209 endocrinology & metabolism Disease Type 2 diabetes 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Weight loss Internal medicine Diabetes mellitus Internal Medicine medicine Intensive care medicine education Glycemic Advanced and Specialized Nursing Canagliflozin education.field_of_study business.industry medicine.disease Transplantation medicine.symptom business medicine.drug |
| Zdroj: | Diabetes care. 40(7) |
| ISSN: | 1935-5548 |
| Popis: | Diabetes is highly prevalent in kidney transplant recipients (KTR). Simultaneous pancreas-kidney transplant recipients (SPKTR) are also at risk for developing type 2 diabetes following transplantation, when insulin secretion may be insufficient to maintain normoglycemia. Transplant-specific risk factors associated with the development of type 2 diabetes include the use of diabetogenic immunosuppressive medications, hypomagnesemia, and posttransplant weight gain (1). In nontransplant populations with type 2 diabetes and established cardiovascular (CV) disease, the use of sodium–glucose cotransporter 2 inhibitors (SGLT2i) can improve glycemic control, promote weight loss, and reduce the risk of CV events (2). Given the increased incidence of posttransplant diabetes and the high CV burden in transplant recipients, the use of SGLT2i in this population is attractive. Of concern, however, is the lack of safety data regarding SGLT2i in transplant recipients. The purpose of this study is to describe our short-term experience of KTR and SPKTR treated with canagliflozin at our institutions. All adult KTR or SPKTR … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|